Investor Relations

Chemomab Completes Merger with Anchiano Therapeutics (READ MORE)(March 16, 2021)
– Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol “CMMB
– Combined company will focus on advancing Chemomab’s CM-101 currently in Phase 2 for rare fibrotic indications

Contact:
Investor Relations: Irina Koffler, LifeSci Advisors, LLC
Phone: +1-917-734-7387         
Email: ir@chemomab.com

Chemomab Therapeutics: Sharon Elkobi, VP, Business Development
Phone: +972773310156
Email: bd@chemomab.com

Visit Chemomab online at www.chemomab.com

We are located in Cambridge, MA and are publicly traded on the Nasdaq (NASDAQ: ANCN).

Stock Quote

Nasdaq

Intraday delay: 15 minutes

Stock Chart 

Intraday delay: 15 minutes

Press Releases

Chemomab Completes Merger with Anchiano Therapeutics (March 16, 2021)
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing (March 15, 2021)
Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis (February 2, 2021)
Chemomab Announces Positive Phase Ib Results of its SPARK Study Testing CM-101 in NAFLD Patients (January 4, 2021)
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement (December 15, 2020)
Anchiano Appoints Stan Polovets as Chairman of the Board (May 26, 2020)
Anchiano Therapeutics Reports First Quarter 2020 Financial Results (May 11, 2020)
Anchiano Appoints Steve DiPalma as Chief Financial Officer (May 5, 2020)
Anchiano to Hold Virtual Meeting of Shareholders (April 17, 2020)
Anchiano Therapeutics Reports Year-End 2019 Financial Results (March 18, 2020)
Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders (January 17, 2020)
Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update (November 15, 2019)
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program (November 15, 2019)
Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board (October 24, 2019)
Anchiano Therapeutics Enters Into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs (September 23, 2019)
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference (September 20, 2019)
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results (August 5, 2019)
Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange (June 18, 2019)
Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development (May 29, 2019)
Anchiano Therapeutics Reports First Quarter 2019 Financial Results (May 22, 2019)
Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference (March 14, 2019)
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Sock Exchange (March 14, 2019)
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results  (March 12, 2019)
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering  (February 14, 2019)
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering  (February 12, 2019)
Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering (January 7, 2019)
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (November 26, 2018)
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer (November 26, 2018)

READ MORE

SEC Company Filings



Filing DateForm (Link to docs.)DescriptionDownload
21-03-178-KCurrent report, items 1.01, 2.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.07, and 9.01PDF
21-03-108-KCurrent report, item 8.01PDF
21-03-10425Prospectuses and communications, business combinationsPDF
21-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]PDF
21-03-09425Prospectuses and communications, business combinationsPDF
21-02-12424B3Prospectus [Rule 424(b)(3)]PDF
21-02-10EFFECTNotice of EffectivenessPDF
21-02-10S-4/ARegistration of securities, business combinations [Amend] PDF
21-02-088-KCurrent report, item 8.01PDF
21-02-08425Prospectuses and communications, business combinationsPDF
21-02-02425Prospectuses and communications, business combinationsPDF
21-01-13S-4Registration of securities, business combinationsPDF
21-01-11425Prospectuses and communications, business combinationsPDF
21-01-05425Prospectuses and communications, business combinationsPDF
20-12-158-KCurrent report, items 1.01, 8.01, and 9.01PDF
20-12-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialPDF
20-11-1610-QQuarterly report [Sections 13 or 15(d)]PDF
20-10-208-KCurrent report, item 5.02PDF
20-08-1410-QQuarterly report [Sections 13 or 15(d)]PDF
20-07-158-KCurrent report, item 5.02PDF
20-07-098-KCurrent report, items 5.02 and 8.01PDF
20-05-218-KCurrent report, item 5.02PDF
20-05-0710-QQuarterly report [Sections 13 or 15(d)]PDF
20-05-068-KCurrent report, items 5.02, 7.01, and 9.01PDF
20-04-248-KCurrent report, item 5.07PDF
20-04-17DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialPDF
20-04-158-KCurrent report, item 3.01PDF
20-03-30Pre 14AOther preliminary proxy statementsPDF
20-03-17S-8Securities to be offered to employees in employee benefit plansPDF
20-03-1710-KAnnual report [Section 13 and 15(d), not S-K Item 405]PDF
20-03-168-KCurrent report, item 8.01PDF
20-02-108-KCurrent report, items 5.02 and 8.01PDF
20-02-048-KCurrent report, items 2.05, 7.01, and 9.01PDF
20-01-318-KCurrent report, item 8.01PDF
20-01-108-KCurrent report, item 8.01PDF
20-01-028-KCurrent report, items 5.02 and 8.01PDF
19-11-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-11-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-07-22S-8Securities to be offered to employees in employee benefit plansPDF
19-07-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-05-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-04-2420-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] [Amend] PDF
19-03-2520-KAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
19-03-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-03-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-02-13424B4Prospectus [Rule 424(b)(4)]PDF
19-02-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
19-02-11F-1/ARegistration statement for certain foreign private issuers [Amend] PDF
19-02-088-A12BRegistration of securities [Section 12(b)]PDF
19-02-08F-1/ARegistration statement for certain foreign private issuers [Amend] PDF
19-02-07F-1/ARegistration statement for certain foreign private issuers [Amend] PDF
19-01-30F-1/ARegistration statement for certain foreign private issuers [Amend] PDF
19-01-07F-1Registration statement for certain foreign private issuers PDF
View in new page (click here)
Anchiano Therapeutics Ltd. CIK#: 0001534248

Presentations and Events

Chemomab Corporate Overview | March 9-10, Global Life Sciences Conference

View/Download PDF 

Filed by Anchiano Therapeutics Ltd. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended
Subject Company: Chemomab Ltd.

Chemomab Corporate Overview | January 2021

View/Download PDF 

Filed by Anchiano Therapeutics Ltd. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended
Subject Company: Chemomab Ltd.

Corporate Presentation | July 2020

View/Download PDF 

Ladenburg Thalmann 2019 Healthcare Conference | September 24, 2019

Click here for webcast 

View/Download PDF

Corporate Update Call | September 24, 2019

Link

Baird’s 2019 Global Healthcare Conference | September 5, 2019

Click here for webcast 

View/Download PDF

MIXiii-BIOMED 2019 | May 16, 2019 

View/Download PDF

Oppenheimer 29th Annual Healthcare Conference | March 20, 2019 

View/Download PDF